MEPE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals

This MEPE Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report.

Review date: 16 October 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement. “Claimed” is a database annotation that still requires family consolidation, live-claim review and jurisdiction-specific claim construction.

Executive sequence-risk thesis

MEPE is a protein directed to Matrix extracellular phosphoglycoprotein. Public therapeutic sequence data from UniProtKB/Swiss-Prot reviewed human protein record supplied the query material: Full-length protein 525 aa. PatSnap’s all-patent protein search returned a closest review hit at 100.00% query identity across 525/525; the returned record was marked No.

The screening conclusion is moderate-to-elevated diligence priority, not “blocked” or “clear.” Similarity is most informative when interpreted by chain, CDR/framework location, construct architecture, target evidence and the language of live claims. Constant-region reuse or a common light chain can produce high percentages without proving asset-level collision, while a small number of substitutions in a CDR or linker junction can be disproportionately important.

Sequence scope and MCP workflow

The review began with traceable UniProtKB/Swiss-Prot reviewed human protein record query sequences. Each full-length protein query was run with the current consolidated ls_sequence_search workflow against ALLPATENT and CLAIMS protein records, allowing gaps, using E-value ≤1×10⁻³ and a 20-record task cap. The closest informative hit was resolved with ls_sequence_fetch and compared using ls_sequence_alignment. Where a patent identifier was available, ls_patent_sequence_fetch retrieved linked sequence records; ls_antibody_antigen_search supplied target and antibody context. The legacy ls_sequence_search_submit and ls_sequence_search_get_results endpoints are no longer used for new reports because Biology Modality now recommends ls_sequence_search.

Similarity search readout

The largest chain-level result set contained 20 records. These are search records, not unique inventions, enforceable claims or independent families. Publications can repeat the same sequence across jurisdictions, examples, comparators and continuations. Deduplication by earliest priority, applicant, simple family and legal status is required before business conclusions.

Module-level reading of the construct

The available query set contains 1 independently searchable chain module(s). For this single-pair format, heavy- and light-variable evidence should still be interpreted together. A highly conserved light chain can be shared across unrelated heavy chains, while a heavy-chain match may include common framework and constant-region sequence outside the specificity-defining CDRs.

The chain totals also provide a practical specificity check. A chain that repeatedly reaches the task cap is less discriminating at the raw-sequence level than a chain with a smaller, concentrated result set. Reviewers should therefore prioritize the rarest domain or junction, then use the more widely reused chain as corroboration. This ordering reduces the risk of treating platform-level or germline similarity as evidence of an asset-level collision.

Pairwise alignment: what the closest hit means

The selected Full-length protein query comparison reported 525/525 identical positions, query coverage 525/525, E-value 0 and 0/525 gaps. The matched subject sequence was resolved as sequence 438943, 1,110 aa, annotated “unnamed sequence”.

Percentage identity alone is not a claim chart. The next review should map every mismatch to IMGT/Kabat position, CDR or framework, constant region, linker boundary and any claimed SEQ ID. For multispecific assets, each arm should also be searched independently because a full-construct query can obscure highly conserved binding modules.

Antibody–antigen and patent-sequence evidence

The short asset-name query returned 2 keyword records, but the leading relation is annotated to MEPERIDINE, not MEPE. The leading record was US12065507B2, “Compounds and methods for use in connection with opioid use disorders”. This is an alias-collision warning rather than direct antibody–antigen evidence for Matrix extracellular phosphoglycoprotein.

ls_patent_sequence_fetch returned 72 associated sequences for US12065507B2, but that record is linked to MEPERIDINE, not MEPE. These sequences are retained as an alias-collision control and must not be attributed to the reviewed target without independent confirmation.

Evidence strength and blind spots

The evidence is strongest for the exact query sequences, the returned alignment coordinates and the patent records directly resolved by the MCP tools. It is weaker where therapeutic aliases are absent, where a publication supplies fragments instead of the administered construct, or where the result set is capped before all lower-ranked families are reviewed. Antibody names can also refer to a parental molecule, biosimilar, anti-drug antibody or comparator; the underlying sequence and target annotation must be read before attributing a record to MEPE.

Patent sequence listings are deliberately broad and can contain screening libraries, consensus sequences, controls, antigens, primers and manufacturing elements alongside candidate therapeutics. Conversely, relevant claims may define a molecule through CDR combinations, percentage-identity thresholds, functional binding language or genus formulas without reproducing the exact commercial sequence. This is why the report combines sequence similarity with antibody–antigen evidence and still stops short of a legal conclusion.

Patent-risk interpretation

Diligence actions

1. Confirm that the reviewed sequence matches the clinical or commercial construct rather than an early lead or analytical reference.
2. Repeat searches for CDR-only queries, junctions and nucleotide sequences, then cluster records by patent family.
3. Annotate each high-identity hit by VH/VL domain, CDR, framework, Fc and linker position.
4. Retrieve the underlying sequence listing and verify the returned sequence number and “claimed” annotation against the filed document.
5. Build jurisdiction-specific claim charts for live families and document licenses or platform rights affecting Matrix extracellular phosphoglycoprotein programs.
6. Rerun the MCP workflow at the transaction or development decision date because sequence and legal-status coverage changes.

Bottom line

MEPE has a traceable therapeutic sequence. The combination of 100.00% closest-hit identity, No claim annotation, and an alias-collision set led by MEPERIDINE rather than direct MEPE evidence, with 72 sequences linked to that unrelated leading record supports moderate-to-elevated diligence priority. The defensible outcome is a prioritized, domain-aware family and claim review—not a binary clearance statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Query sequences: UniProtKB/Swiss-Prot reviewed human protein record. Core similarity, sequence, alignment, patent-sequence and antibody–antigen evidence was retrieved through PatSnap Biology Modality MCP on 16 October 2026. Database annotations and legal status can change; rerun at the decision date.